Related Experiment Videos
First-pass metabolism of pentamethylmelamine in the rat liver
Abstract:
The disposition of pentamethylmelamine (PMM) was studied in the male Wistar rat. PMM (5 mg/kg) was administered intraarterially, i.v. (5 and 10 mg/kg), via the portal vein, and into the duodenum to cannulated and unanesthetized rats (n greater than or equal to 4) via infusion. Parent compound and metabolites were quantified by gas chromatography. The areas under the plasma concentration-time curves of PMM after intraarterial and i.v. administration were equal and twice as large as the areas after portal vein and intraduodenal administration. This indicated insignificant lung metabolism for PMM; the low bioavailability of PMM when given via the portal vein or intraduodenally (in both cases, some 50% of an i.v. dose) was the result of presystemic metabolism in the liver. PMM was completely absorbed after intraduodenal administration, and no intestinal metabolism was observed. Linear kinetic behavior of i.v. PMM was observed in the 5- to 10-mg/kg dose range. The area under the plasma concentration-time curve of the first metabolite N2,N2,N4,N6-tetramethylmelamine was significantly greater when PMM was given via the portal vein or intraduodenally than when given intraarterially or i.v. This indicated either extrahepatic elimination/renal excretion of PMM or the existence of an additional metabolic pathway. However, experiments with adrenalectomized rats and rats with ligated blood flow to the kidneys did not alter the area for the first metabolite. These findings may be explained by the formation of unknown metabolites and/or reactive intermediates of PMM.
Insights
Pentamethylmelamine (PMM) disposition in rats shows liver metabolism reduces bioavailability when administered orally or via the portal vein. Lung metabolism is insignificant, but unknown metabolites may form.
Area of Science:
- Pharmacokinetics and Drug Metabolism
- Toxicology
- Bioavailability Studies
Background:
- Pentamethylmelamine (PMM) is a compound requiring pharmacokinetic evaluation.
- Understanding drug disposition is crucial for assessing efficacy and safety.
- Presystemic metabolism significantly impacts oral bioavailability.
Purpose of the Study:
- To investigate the pharmacokinetic disposition of pentamethylmelamine (PMM) in male Wistar rats.
- To determine the bioavailability of PMM following different administration routes.
- To identify potential sites of PMM metabolism and excretion.
Main Methods:
- Administered PMM (5 mg/kg) via intraarterial, intravenous (5 and 10 mg/kg), portal vein, and intraduodenal routes in cannulated rats.
- Quantified parent compound and metabolites using gas chromatography.
- Analyzed plasma concentration-time curves to determine pharmacokinetic parameters.
Main Results:
- Intraarterial and intravenous PMM administration yielded equal plasma concentration-time curves.
- Portal vein and intraduodenal administration resulted in approximately 50% lower bioavailability compared to intravenous.
- Complete absorption occurred after intraduodenal administration, with no observed intestinal metabolism, indicating hepatic presystemic metabolism.
- The first metabolite, N2,N2,N4,N6-tetramethylmelamine, showed increased levels with portal vein/intraduodenal routes, suggesting extrahepatic pathways or unknown metabolites.
Conclusions:
- Hepatic presystemic metabolism significantly reduces PMM bioavailability after oral or portal vein administration.
- Lung metabolism of PMM is negligible.
- The increased metabolite levels suggest potential extrahepatic elimination or novel metabolic pathways for PMM, warranting further investigation into unknown metabolites.